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LETTER
Inaccurate clinical nodal staging
of non-small cell lung cancer:
evidence from the MRC LU22
multicentre randomised trial
The clinical staging of non-small cell lung
cancer (NSCLC) is of paramount importance.
It determines prognosis and therapy, and
inaccurate stagingmay result in inappropriate
treatment. In particular, clinical staging that
misses mediastinal metastases may result in
the patient undergoing a futile thoracotomy.
Conversely, accurately detecting mediastinal
metastases preoperatively would allow
consideration of concurrent chemoradiotherapy
or neoadjuvant treatment.
Although sensitivity and speciﬁcity data
of CT scanning, positron emission tomog-
raphy (PET) and mediastinoscopy for the
detection of mediastinal metastases exist,
the impact on patient outcomes when
combined with other standard staging tech-
niques such as mediastinoscopy is limited.
The MRC LU22 trial,1 which compared
surgery alone with neoadjuvant chemo-
therapy followed by surgery, collected
prospective data on clinical and pathological
staging and therefore allows a comparison of
clinical mediastinal node staging with path-
ological staging from mediastinal lymph
node dissection at surgery.
Of the 519 patients in theMRC LU22 trial,
261 were randomised to undergo surgery
alone. Detailed clinical and pathological
staging were available for 230 of these
patients, and 67 were reported as having
had a PET scan. Nineteen of these patients
underwent mediastinoscopy or anterior
mediastinotomy for PET-positive medias-
tinal lesions. The 67 patients who had
a PET scan were clinically staged as having
no evidence of mediastinal disease preop-
eratively (cN0e1), but 8 (12%; 95% CI 4%
to 20%) were subsequently found at oper-
ation to have mediastinal (pN2) metas-
tases. A further 9 patients were also
understaged as hilar disease was missed
preoperatively (ie, they were considered
cN0 but were pN1), but this would not
have affected the decision to operate.
Overall, 17 patients (25%; 95% CI 15% to
36%) were understaged despite the use of
preoperative PET scanning (table 1).
PET and mediastinoscopy are comple-
mentary techniques that are currently
considered to be the gold standard for the
clinical mediastinal staging of NSCLC.
However, in this trial, clinical staging with
PET and mediastinoscopy for PET-positive
mediastinal lesions failed to detect medias-
tinal metastases in 12% of patients and,
overall, the nodal status was understaged in
25%. PET-negative mediastinal nodes may
harbour malignant cells and invasive
sampling of enlarged nodes has been recom-
mended, regardless of metabolic activity on
the PET scan.2 Mediastinoscopy (or other
invasive mediastinal sampling) is required for
the clariﬁcation of PET-positive mediastinal
lesions. However, mediastinoscopy is under-
used in clinical practice3 and, when
performed, can only access the upper and
anterior mediastinum.
In order to improve preoperative medias-
tinal lymph node staging, current guidelines
recommend invasive mediastinal staging for
patients with central tumours, ﬂuorodeox-
yglucose (FDG)-avid hilar N1 disease, low
FDG uptake of the primary tumour and
lymph nodes $10 mm on the CT scan
regardless of FDG uptake.2 Newer tech-
niques such as endoscopic ultrasound (EUS)
and endobronchial ultrasound (EBUS) for the
minimally invasive mediastinal staging of
NSCLC are emerging, and their sensitivities
for detecting mediastinal metastases appear
to be superior to the standard techniques of
CT, PET and mediastinoscopy. Preliminary
results from a randomised trial have shown
that routine use of EUS improves clinical
staging and signiﬁcantly reduced the rate of
futile thoracotomies from 25% to 9%.4
Further data are required on the impact of
EBUS, EUS and their combination on the
accuracy of clinical staging and the selection
of operative candidates.
Improving the detection of mediastinal
disease preoperatively would be an impor-
tant step forward in optimising the selection
of patients for surgery and identifying those
who may beneﬁt from neoadjuvant chemo-
therapy or chemoradiotherapy.
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Table 1 Clinical and pathological staging of patients with non-small cell lung cancer who
underwent positron emission tomography and thoracotomy
pN0 pN1 pN2 Total
cN0 28 9 6 43
cN1 13 9 2 24
Total 41 18 8 67
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